Illumina, Inc.
Illumina Completes Acquisition of SomaLogic to Expand Proteomics Capabilities
Summary
On January 30, 2026, Illumina, Inc. completed its acquisition of SomaLogic from Standard BioTools for $350 million in cash, subject to customary adjustments, and up to $75 million in potential milestone payments. The acquisition, which was first disclosed in June 2025, includes SomaLogic's proteomics technology and businesses, excluding Standard BioTools's mass cytometry and microfluidics businesses. This strategic move aims to expand Illumina's multiomics portfolio and strengthen its position in the proteomics market, enabling faster drug discovery and improved healthcare outcomes.
Profitelligence Alerts
Get alerts for ILMN
Be first to know when Illumina, Inc. files with the SEC.
Filing Categories
Advertisement
About Illumina, Inc.
Illumina, Inc. operates as a global leader in the life sciences industry, focusing on the development and manufacturing of integrated systems for the analysis of genetic variation and function. Primarily, Illumina’s products and services are pivotal in advancing genomic research, enabling scientists to explore DNA sequencing and genetic mapping with high precision and efficiency. The company’s solutions are extensively utilized in fields such as oncology, reproductive health, and genetic disease diagnostics. Known for its cutting-edge sequencing tools, Illumina plays a crucial role in driving innovation in personalized medicine, helping to tailor medical treatments to individual genetic profiles. Headquartered in San Diego, California, Illumina contributes significantly to the genomics sector’s expansion, supporting initiatives in health and medicine, agrigenomics, and microbiology. By providing critical tools for genetic analysis, Illumina aids researchers and clinical laboratories worldwide, influencing how healthcare is approached and offering insights into complex biological systems.
Official SEC Documents
Advertisement